−Removed: Unregistered Sales of Equi ty Securities and Use of Proceeds.
+Added: Unregistered Sales of Equity Securities and Use of Proceeds.
Unregistered Sales of Equity Securities
−Removed: We did not sell or issue any equity securities during the three months ended September 30, 2020 that were not registered under the Securities Act of 1933, as amended, or the Securities Act.
+Added: We did not sell or issue any equity securities during the three months ended March 31, 2021 that were not registered under the Securities Act of 1933, as amended, or the Securities Act.
Use of Proceeds from Initial Public Offering of Common Stock
5 unchanged sentences
No offering expenses were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning 10% or more of any class of our equity securities or to any other affiliates.
−Removed: As of September 30, 2020, we used approximately $11.0 million of the net proceeds from the IPO to fund the development of Haduvio for the treatment of pruritus associated with prurigo nodularis, the treatment of chronic cough in patients with IPF and general corporate purposes.
−Removed: There has been no material change in our planned use of the net proceeds from the IPO as described in our final prospectus for the IPO filed with the SEC p ursuant to Rule 424(b ) under the Securities Act .
+Added: As of March 31, 2021, we used approximately $27.4 million of the net proceeds from the IPO to fund the development of Haduvio for the treatment of pruritus associated with prurigo nodularis, the treatment of chronic cough in patients with IPF and general corporate purposes.
+Added: There has been no material change in our planned use of the net proceeds from the IPO as described in our final prospectus for the IPO filed with the SEC pursuant to Rule 424(b ) under the Securities Act .
We have invested the net proceeds from the IPO in money market funds.
−Removed: Loan and Security Agreement, dated as of August 13, 2020, between Silicon Valley Bank and Trevi Therapeutics, Inc.
−Removed: Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
−Removed: Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
−Removed: Certification of Principal Executive Officer Pursuant to 18 U.S.C.
−Removed: Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
−Removed: Certification of Principal Financial Officer Pursuant to 18 U.S.C.
+Added: Certification of Principal Executive Officer and Principal Financial Officer Pursuant to Rules 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
+Added: Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C.
Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
8 unchanged sentences
TREVI THERAPEUTICS, INC.
−Removed: November 12, 2020
−Removed: /s/ Christopher Seiter
−Removed: Christopher Seiter
−Removed: Chief Financial Officer
−Removed: (Principal Financial Officer)
+Added: /s/ Jennifer Good
+Added: Jennifer Good
+Added: President and Chief Executive Officer
+Added: (Principal Executive Officer
+Added: and Principal Financial Officer)
+Added: /s/ Christopher Galletta
+Added: Christopher Galletta
+Added: Controller and Treasurer
+Added: (Principal Accounting Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.